文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

Aficamten在非梗阻性肥厚型心肌病中的全球疗效:ACACIA-HCM研究结果

Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy: Results From ACACIA-HCM.
PubMed 文献 · Circulation · 2026-08-28

ACACIA-HCM试验将症状性非梗阻性肥厚型心肌病患者随机分配至阿夫凯泰(aficamten)组(n=258)或安慰剂组(n=259),评估36周时多项临床指标。结果显示阿夫凯泰在症状负担、左房容积指数、间隔e'及NT-proBNP等指标上均优于安慰剂,部分或完全临床应答率(≥3项改善)为53%对14%(P<0.001)。

要点

  • 阿夫凯泰在症状负担、左房容积指数、间隔e'和NT-proBNP方面均显著优于安慰剂。
  • 部分或完全临床应答(≥3项改善)率阿夫凯泰组53%,安慰剂组14%(P<0.001)。
  • 峰值氧摄取量改善两组差异未达统计学显著性(P=0.1)。

核心结论

  • 在非梗阻性肥厚型心肌病患者中,阿夫凯泰与症状负担和舒张功能等多方面临床相关指标的改善相关。

研究设计与样本

  • ACACIA-HCM试验为随机对照试验,症状性非梗阻性肥厚型心肌病患者随机接受每日阿夫凯泰(n=258)或安慰剂(n=259),第36周评估。

主要发现

  • 第36周,阿夫凯泰组与安慰剂组分别有71%与53%的患者症状负担改善。
  • 峰值运动能力改善率分别为45%与37%(P=0.1)。
  • 左房容积指数改善率分别为31%与23%,间隔e'改善率分别为51%与26%,NT-proBNP降低≥50%的比例分别为63%与5%(除峰值氧摄取外P<0.05)。
  • 阿夫凯泰相对安慰剂的需治疗人数(NNT)范围从1.7(NT-proBNP降低)到14(峰值氧摄取改善)。
  • 部分或完全临床应答(≥3项改善)率阿夫凯泰组53%,安慰剂组14%(P<0.001)。

关键数值与推荐

  • 临床应答综合5项指标:症状负担改善、峰值氧摄取量增加≥0.5 mL/kg/min、左房容积指数降低>10%、间隔e'改善>10%、NT-proBNP降低≥50%。
  • 总体临床应答分为无应答(0项)、有限(1或2项)、部分(3或4项)、完全(5项)。

临床怎么用

  • 对于症状性非梗阻性肥厚型心肌病患者,阿夫凯泰可能改善症状负担和舒张功能等多维度指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Nonobstructive hypertrophic cardiomyopathy (nHCM) is associated with significant morbidity with no approved treatment. Aficamten is a cardiac myosin inhibitor targeting excess contractility and diastolic impairment, the predominant mechanism responsible for adverse outcomes in nHCM. In the ACACIA-HCM trial (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints in Adults With Non-Obstructive HCM; URL: https://www.clinicaltrials.gov; Unique identifier: NCT06081894), aficamten significantly improved outcomes in patients with nHCM versus placebo. To contextualize the observed treatment effects, we performed a responder analysis integrating multiple clinically relevant measures. METHODS: Patients with symptomatic nHCM were randomized to daily aficamten (n=258) or placebo (n=259) assessed at week 36, including (1) symptom burden (≥1 improvement in New York Heart Association class or reported improvement in Patient Global Impression of Change); (2) exercise capacity (≥0.5 mL/kg per min in peak oxygen uptake); (3) >10% decrease in left atrial volume index; (4) >10% improvement in septal early diastolic mitral annular velocity (e'); (5) ≥50% reduction in NT-proBNP (N-terminal pro-B-type natriuretic peptide). Overall clinical response was classified by the number of favorable outcomes achieved: nonresponder (none), limited (1 or 2), partial (3 or 4), or complete (all 5). RESULTS: At 36 weeks, a greater proportion of patients treated with aficamten versus placebo experienced improvements in symptom burden (71% versus 53%), peak exercise capacity (45% versus 37%), left atrial volume index (31% versus 23%), septal e' (51% versus 26%), and NT-proBNP (63% versus 5%) (P<0.05 for all except peak oxygen uptake, P=0.1). Number needed to treat for aficamten ranged from 1.7 (NT-proBNP reduction) to 14 (peak oxygen uptake improvement) relative to placebo. A partial or complete clinical response (≥3 outcomes) was achieved in 53% of patients on aficamten versus 14% on placebo (P<0.001). CONCLUSIONS: In patients with nHCM, aficamten was associated with improvements across a broad range of clinically relevant measures including symptom burden and diastolic function. These results underscore a potential benefit of aficamten in the population of patients with nHCM. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT06081894.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Maron MS, Masri A, Bhatia A, et al. Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy: Results From ACACIA-HCM. Circulation. 2026. PMID: 42663111. doi:10.1161/CIRCULATIONAHA.126.082026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。